Eurocine Vaccines contracts Artemis Bioservices as CRO
Eurocine Vaccines AB (publ) ("Eurocine Vaccines" or "the Company") announces today that the Company has contracted Artemis Bioservices B.V. (”Artemis Bioservices”) as a CRO (Contract Research Organization) for the upcoming preclinical studies with its mRNA-based vaccine candidate against Herpes Simplex Virus type 2 (HSV-2). The first preclinical study is planned to start as soon as sufficient funding has been secured through the ongoing unit issue, and to be conducted during the first half of 2024.
Eurocine Vaccines is a development company that bridges the gap between innovations and market needs in the highly active vaccine field. The Company believes that the vaccine field offers great profitability for successful projects. Eurocine Vaccines' focus is to accelerate the development of the Company's therapeutic vaccine candidate against HSV-2, one of the most widespread infectious diseases in humanity.
Eurocine Vaccines is now planning to conduct preclinical studies with the Company's therapeutic mRNA vaccine against HSV-2. These studies aim to evaluate the immune system's potential to combat an established HSV-2 infection in guinea pigs after vaccination. This research is of utmost importance in preparing the Company for the upcoming development phases, including clinical trials on patients infected with HSV-2. Given that Eurocine Vaccines receives sufficient funding through the ongoing unit issue, the Company plans to begin the development plan with a first preclinical study, to be conducted during the first half of 2024.
Today, Eurocine Vaccines announces that an agreement has been signed with Artemis Bioservices as CRO. Through the agreement with Artemis Bioservices, well known for their expertise in the development of antiviral drugs and vaccines, Eurocine Vaccines strengthens its research capacity. This collaboration is an important step to initiate the first preclinical study with guinea pigs and will contribute to implementing the Company's overall research and development strategy.
”We are very pleased to have settled an agreement with Artemis Bioservices today, which ranked highest in our thorough selection process. Artemis Bioservices' unique combination of specialist knowledge in preclinical HSV-2 models, scientific expertise, and excellent references make them our preferred partner in the development of a therapeutic HSV-2 vaccine. We are excited to add Artemis Bioservices to our network of partners and look forward to a successful and rewarding collaboration,” says Karl Ljungberg, Head of Preclinical Development at Eurocine Vaccines.
”Our collaboration with Artemis Bioservices is an important step in strengthening and preparing our preclinical studies for the HSV-2 vaccine. Through this partnership, we ensure access to valuable expertise and experience, which is crucial for our upcoming studies to maintain the highest possible quality and where we create a robust scientific basis for our HSV-2 vaccine," comments CEO, Hans Arwidsson.
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.
Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.
Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.